Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.

ABSTRACT:

Background

In relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here defined as a switch to a lower efficacy therapy, is often considered by patients and physicians, but evidence to guide such decisions is scarce. In this study, we aimed to compare clinical outcomes between patients who de-escalated therapy versus those who continued their therapy.

Methods

In this retrospective analysis of data from an observational, longitudinal cohort of 87,239 patients with multiple sclerosis (MS) from 186 centers across 43 countries, we matched treatment episodes of adult patients with RRMS who underwent treat

SUBMITTER: Muller J 

PROVIDER: S-EPMC11909097 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature